Pending AI
Monday, June 03, 2024
Company Presentation
![Platform for Therapeutics](https://cdn.asp.events/CLIENT_BIO_7BB99CBA_BAD1_B8C8_CF9F25DA29A80CC6/sites/BIOIC-2024/media/icons/seminars/blank.png)
Company Presentation Theater 4
Pending AI has developed a comprehensive discovery platform enabled by artificial intelligence and quantum mechanics, ushering in a new paradigm of medicinal innovation where higher-quality small molecule drugs can be developed in a fraction of the time and cost. The company's capabilities include but are not limited to: 1) Generative Molecule Designer (automated and ultra-high-throughput production of novel pharmacological scaffolds), 2) Retrosynthesis Engine (rapid prediction of synthesis pathways to any given query molecule) and 3) Quantum Refinement of Protein Structures (higher-quality crystal structures for biological targets, improving the likelihood of virtual screening campaign success). Pending AI is actively seeking research-and-development partnerships with pharmaceutical companies, as well as ascertaining interest from investors in the company's upcoming investment round.
![Pending AI](https://www.abstractscorecard.com/uploads/Tasks/upload/21754/XDQDGWMO-1821939-1-JPG.png)
Company Website:
https://www.linkedin.com/company/14425621/
Lead Product in Development:
Drug discovery platform enabled by artificial intelligence and quantum mechanics.
Company HQ City
Cambridge
Company HQ State
Massachusetts
Company HQ Country
United States
CEO/Top Company Official
Dr. Mark Waller (Founder/CEO)
Development Phase of Primary Product
Discovery
Primary Speaker